Angel investors
What assumptions drive an angel valuation discussion for a healthcare software startup?
a healthcare software startup: A valuation discussion should make the assumptions and the investment instrument visible.
A valuation discussion should make the assumptions and the investment instrument visible. Comparisons can inform the discussion without establishing a correct price. Distinguish price, ownership, dilution, rights, and the capital needed to reach future milestones.
Start with the decision
Use a hypothetical ownership bridge to expose the effect of round size and pricing assumptions. Compare actual terms with qualified advisers. Do not translate a market multiple or another company's financing into a personalized recommendation.
The illustrative scenario
This is an educational workbook. The company or fund and all numerical inputs below are fictional. They are not ADIN results, customer claims, market benchmarks, or a forecast.
The fictional team is piloting an administrative scheduling product with a provider group. Staff use it in a narrow workflow, while procurement and data review determine whether a broader rollout is possible.
A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval.
A simplified priced-round and cash comparison
Assume a fictional priced equity round of $3,500,000.00 at a pre-money value of $14,000,000.00. A $35,000.00 check divided by the simplified post-money amount produces 0.200% ownership. If a later issuance reduces existing holders by an assumed 20%, that interest becomes 0.160% without participation.
The exercise omits option pools, convertibles, preferences, fees, side agreements, and other actual terms. It is not a SAFE conversion model or a recommendation to invest or preserve ownership. Actual cap-table and document analysis belongs with qualified advisers. A percentage of ownership does not specify eventual proceeds or protect against total loss.
The fictional company's $900,000.00 of cash divided by $110,000.00 of monthly use gives 8.2 months under a constant-use assumption. Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence. Connect that simple quotient to dated obligations and milestones before drawing a conclusion about financing needs or progress.
| Item | Illustration |
|---|---|
| Assumed pre-money value / round size | $14,000,000.00 / $3,500,000.00 |
| Fictional investor check | $35,000.00 |
| Simplified initial ownership | 0.200% |
| Assumed later dilution | 20% |
| Ownership without later participation | 0.160% |
| Cash / constant monthly use | $900,000.00 / $110,000.00 |
Use this worksheet
Answer the questions with a source, date, owner, and next action. Mark an unknown as unknown. Use public or permissioned information and involve a qualified specialist when a question requires expertise beyond the team’s competence.
- What instrument is proposed?
- What ownership follows under the terms?
- What dilution is possible?
- What rights accompany the interest?
- Which comparison is genuinely relevant?
Questions specific to this scenario
- Which workflow is actually in scope?
- Who approves data access?
- What specialist review is needed?
Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet.
A concrete next test
Ask the authorized workflow owner to map a narrow administrative use case without disclosing patient information. Identify the data-access and procurement approvals needed for the next step. Keep operational adoption evidence separate from claims about clinical benefit or regulatory status.
Interpret the result
Simple arithmetic can clarify a discussion while omitting option pools, convertibles, fees, preferences, and later terms. State those omissions before using the model to assess a real transaction.
Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence.
Sources and method
These primary resources provide background for the concepts. The fictional scenario, calculations, and worksheet are ADIN educational examples; the sources do not report or validate those invented results. Reviewed October 11, 2026.